Skip to Main content Skip to Navigation
Journal articles

AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Francois Lux 1, 2 Vu Long Tran 1, 3 Eloise Thomas 1 Sandrine Dufort 2 Fabien Rossetti 1 Matteo Martini 1 Charles Truillet 4 Tristan Doussineau 2 Guillaume Bort 1 Franck Denat 5 Frédéric Boschetti 6 Goran Angelovski 7 Alexandre Detappe 8 Yannick Crémillieux 9 Nathalie Mignet 10, 11, 12, 13, 14 Bich-Thuy Doan 10, 11, 12, 13, 14 Benoit Larrat 15 Sébastien Mériaux 15 Emmanuel Barbier 16 Stéphane Roux 17 Peter Fries 18 Andreas Müller 18 Marie-Caline Abadjian 19 Carolyn Anderson 19 Emmanuelle Canet-Soulas 20 Penelope Bouziotis 21 Muriel Barberi-Heyob 22 Céline Frochot 23 Camille Verry 24 Jacques Balosso 24 Michael Evans 25 Jacqueline Sidi-Boumedine 26 Marc Janier 26 Karl Butterworth 27 Stephen Mcmahon 27 Kevin Prise 27 Marie-Thérèse Aloy 28, 29 Dominique Ardail 28, 29 Claire Rodriguez-Lafrasse 28, 29 Erika Porcel 30 Sandrine Lacombe 30 Ross Berbeco 8 Awatef Allouch 31 Jean-Luc Perfettini 31, 32 Cyrus Chargari 33, 34, 35, 36 Eric Deutsch 34 Géraldine Le Duc 2 Olivier Tillement 1, 2
1 FENNEC - Formation, élaboration de nanomatériaux et cristaux
ILM - Institut Lumière Matière [Villeurbanne]
24 Equipe 6 : Rayonnement synchrotron et Recherche Médicale
UJF - Université Joseph Fourier - Grenoble 1, CEA - Commissariat à l'énergie atomique et aux énergies alternatives, INSERM - Institut National de la Santé et de la Recherche Médicale : U836, [GIN] Grenoble Institut des Neurosciences
28 PRISME - PRISME
IP2I Lyon - Institut de Physique des 2 Infinis de Lyon
33 Curiethérapie
Département de radiothérapie [Gustave Roussy]
Abstract : AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01935540
Contributor : Noémie Thomas <>
Submitted on : Monday, November 26, 2018 - 5:35:22 PM
Last modification on : Friday, November 13, 2020 - 9:08:03 AM
Long-term archiving on: : Wednesday, February 27, 2019 - 2:55:28 PM

File

Lux, BRJ, 2018.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Francois Lux, Vu Long Tran, Eloise Thomas, Sandrine Dufort, Fabien Rossetti, et al.. AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, British Institute of Radiology, 2019, 92 (1093), pp.20180365. ⟨10.1259/bjr.20180365⟩. ⟨hal-01935540⟩

Share

Metrics

Record views

2366

Files downloads

2091